Appraising Drugs Based on Cost-effectiveness and Severity of Disease in Norwegian Drug Coverage Decisions-Reference-Cited by-同舟云学术

Appraising Drugs Based on Cost-effectiveness and Severity of Disease in Norwegian Drug Coverage Decisions

Published:2022-06-29 Issue:6 Volume:5 Page:e2219503
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Tranvåg Eirik Joakim¹²,Haaland Øystein Ariansen¹,Robberstad Bjarne³,Norheim Ole Frithjof¹²

Affiliation:

1. Bergen Centre for Ethics and Priority Setting, Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway

2. Centre for Cancer Biomarkers, Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway

3. Research Group in Health Economics, Leadership, and Translational Ethics Research, Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2793770/tranvg_2022_oi_220561_1655908688.02735.pdf

Reference42 articles.

1. The real cost of the US health care system.;Emanuel;JAMA,2018

2. Health care spending in the United States and other high-income countries.;Papanicolas;JAMA,2018

3. Novel therapies for an aging population: grappling with price, value, and affordability.;Gurwitz;JAMA,2019

4. American Society of Clinical Oncology guidance statement: the cost of cancer care.;Meropol;J Clin Oncol,2009

5. Delivering affordable cancer care in high-income countries.;Sullivan;Lancet Oncol,2011

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Factors influencing the reimbursement of cancer drugs in Europe: A scoping review;Journal of Evaluation in Clinical Practice;2024-07-03

2. Problems with NICE's severity weights;Social Science & Medicine;2024-05

3. A QALY is [still] a QALY is [still] a QALY?;BMC Medical Ethics;2024-03-23

4. Treating Rheumatoid Arthritis in Zanzibar: a cost effectiveness study comparing conventional, biologic, and targeted-synthetic disease modifying anti-rheumatic drugs;2023-12-06

5. The Role of HTA for Essential Health Benefit Package Design in Low or Middle-Income Countries;Health Systems & Reform;2023-11-10